Pharmaceutical giant AstraZeneca said Saturday that he had resumed a Covid-19 vaccine test after receiving the green light through UK regulators, following a pause in which a British volunteer became ill.
“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, resumed in the UK after confirmation through the Medicines Health Regulatory Authority (MHRA) that it would,” the company said in a statement.
LOOK ALSO Delhi Airport is the first in India to download a Covid lab; how it will work: explained
AstraZeneca announced wednesday that he had “voluntarily suspended” his test of the vaccine developed throughout Oxford University after the volunteer developed an unexplained disease.
An independent committee has been formed to read about safety, which society and the World Health Organization have described as a step of the regimen.
The committee “concluded its investigations and advised the MHRA to resume trials in the UK,” AstraZeneca said.
The AstraZeneca vaccine candidate is one of the world’s applicants lately in phase 3 human trials.
In the United States, the company began recruiting 30,000 volunteers at dozens of sites on August 31, and inoculation is being tested on smaller teams in Brazil and elsewhere in South America.
The AZD1222 vaccine uses a weakened edition of a common cold-causing adenovirus designed to encode the complex protein used by the Covid-19 coronavirus to invade cells.
After vaccination, this protein is produced in the human body, which prepares the immune formula to attack the coronavirus if the user becomes infected later.
“AstraZeneca is committed to protecting trial participants and the highest criteria of conduct in clinical trials,” he said Saturday.
“The company will continue to work with the fitness government around the world and will be guided on when additional clinical trials can be resumed to administer the vaccine in a broad, equitable and unworkable manner in this pandemic. “
“item. title”